Pseudotyped GFP Lentivirus (COV-PSG2)

Product Overview
The Pseudotyped GFP Lentivirus was produced without envelope glycoproteins such as VSV-G or SARS-CoV-2 spike. It contains the eGFP gene driven by a CMV promoter as the reporter. The Pseudotyped GFP Lentivirus can serve as a negative control when studying virus entry initiated by specific interactions between virus particles and receptors.
Nature
Virus
Bio-activity
Since the virus is lacking the envelope glycoproteins and cannot be transfected to target cells, functional titer of this product cannot be determined. Based on p24 values, the approximate lentiviral particles (LP) of this product is ~ 10E+09 LP/ml.
Application Notes
Ideal as a negative control pseudovirus particles for the Pseudotyped GFP rSARS-CoV-2 Spike, CD Cat# COV-PS02 or other pseudovirus particles used to study the mechanism of viral transduction.
Size
1 mL
Buffer
The lentiviruses were produced from HEK293T cells in medium containing 90% DMEM + 10% FBS.
Storage
Store at -80°C. Multiple freeze/thaw cycles not recommended.
When using the virus, transfer the virus from the -80 ° C refrigerator and melt it in an ice bath.
Ship
Frozen on dry ice
Warnings
None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. It is the responsibility of the principal investigator to seek Institutional Biosafety Safety Committee approval for recombinant DNA, transgenic animal or infectious agent use within their laboratory spaces and maintain an Institutional Biosafety Safety Committee approval during the time period these materials are used.

Citations


Have you cited COV-PSG2 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


T cell and antibody responses to SARS-CoV-2: Experience from a French transplantation and hemodialysis center during the COVID-19 pandemic

AMERICAN JOURNAL OF TRANSPLANTATION

Authors: Candon, Sophie; Guerrot, Dominique; Drouot, Laurent; Lemoine, Mathilde; Lebourg, Ludivine; Hanoy, Melanie; Boyer, Olivier; Bertrand, Dominique

Immunosuppressed organ-transplanted patients are considered at risk for severe forms of COVID-19. Moreover, exaggerated innate and adaptive immune responses might be involved in severe progression of the disease. However, no data on the immune response to SARS-CoV-2 in transplanted patients are currently available. Here, we report the first assessment of antibody and T cell responses to SARS-CoV-2 in 11 kidney-transplanted patients recovered from RT-PCR-confirmed (n = 5) or initially suspected (n = 6) COVID-19. After reduction of immunosuppressive therapy, RT-PCR-confirmed COVID-19 transplant patients were able to mount vigorous antiviral T cell and antibody responses, as efficiently as two nontherapeutically immunosuppressed COVID-19 patients on hemodialysis. By contrast, six RT-PCR-negative patients displayed no antibody response. Among them, three showed very low numbers of SARS-CoV-2-reactive T cells, whereas no T cell response was detected in the other three, potentially ruling out COVID-19 diagnosis. Low levels of T cell reactivity to SARS-CoV-2 were also detected in seronegative healthy controls without known exposure to the virus. These results suggest that during COVID-19, monitoring both T cell and serological immunity might be helpful for the differential diagnosis of COVID-19 but are also needed to evaluate a potential role of antiviral T cells in the development of severe forms of the disease.

The Use of POCUS to Manage ICU Patients With COVID-19

JOURNAL OF ULTRASOUND IN MEDICINE

Authors: Schrift, David; Barron, Keith; Arya, Rohan; Choe, Carol

Since the advent of SARS-CoV-2, the virus that causes COVID-19, clinicians have had to modify how they provide high-value care while mitigating the risk of viral spread. Routine imaging studies have been discouraged due to elevated transmission risk. Patients who have been diagnosed with COVID-19 often have a protracted hospital course with progression of disease. Given the need for close follow-up of patients, we recommend the use of ultrasonography, particularly point-of-care ultrasound (POCUS), to manage patients with COVID-19 through their entire ICU course. POCUS will allow a clinician to evaluate and monitor cardiac and pulmonary function, as well as evaluate for thromboembolic disease, place an endotracheal tube, confirm central venous catheter placement, and rule out a pneumothorax. If a patient improves sufficiently to perform weaning trials, POCUS can also help evaluate readiness for ventilator liberation.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket